ArticleMicromachines2025
Microfluidic Nanosensor for Label-Free Multiplexed Detection of Breast Cancer Biomarkers via Surface-Enhanced Reflective FTIR Spectroscopy Using Thin Gold Films and Antibody-Oriented Gold Nanourchin: Feasibility Study.
Article in Micromachines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The simultaneous detection of multiple cancer biomarkers using microfluidic multiplexed immunosensors is gaining significant interest in the field of Point-of-Care diagnostics. This study highlights integrating surface-enhanced infrared Fourier transform (SE-FTIR) with a plasmonic-active nanostructure thin film (PANTF) on a printed circuit board (PCB), housed within a microfluidic device for rapid, non-destructive detection of breast cancer (BC). Detection uses monoclonal antibody (mAb)-functionalized gold nanourchins (GNUs) on dual sensing regions. A total of 12 serum samples (24 data points) were tested for HER-II and CA 15-3. The system demonstrated a SE-FTIR enhancement factor (EF) of ~0.18 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.